Exhibit 99.1
JOINT FILING AGREEMENT
Pursuant to Rule 13d-1(k)(1) of the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the joint filing on behalf of each of them of the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the share capital of MoonLake Immunotherapeutics.
This Joint Filing Agreement may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.
Dated: Darmstadt, August 01, 2022
MERCK HEALTHCARE KGaA, Darmstadt Germany an affiliate of Merck KGaA, Darmstadt, Germany | MERCK HEALTHCARE KGaA, Darmstadt Germany an affiliate of Merck KGaA, Darmstadt, Germany | |||
By: | /s/ Matthias Muellenbeck | By: | /s/ Jens Eckhardt | |
Name: | Matthias Muellenbeck | Name: | Jens Eckhardt | |
Title: | SVP Business Development & Alliance Management | Title: | Head of Legal Business Development |
MERCK KGAA, DARMSTADT, GERMANY | MERCK KGAA, DARMSTADT, GERMANY | |||
By: | /s/ Jens Eckhardt | By: | /s/ Johannes Eckhardt | |
Name: | Jens Eckhardt | Name: | Johannes Eckhardt | |
Title: | Head of Legal Business Development | Title: | Senior Corporate Counsel |
E.MERCK KG, DARMSTADT, GERMANY | E.MERCK KG, DARMSTADT, GERMANY | |||
By: | /s/ Johannes Eckhardt | By: | /s/ Kristin Eibisch | |
Name: | Johannes Eckhardt | Name: | Kristin Eibisch | |
Title: | Attorney-in-Fact | Title: | Attorney-in-Fact |